the generic version of the wonder drug Daclatasvir for treatment of Hepatitis C under the brand name of Daclavir.
Recommended Dosage: The recommended dosage of Daclavir is 60 mg, taken orally, once daily in combination with Sofosbuvir for 12 weeks. Daclavir may be taken with or without food. The optimal duration of Daclavir and Sofosbuvir for patients with cirrhosis has not been established.
Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions: The concomitant use of Daclavir and other drugs may result in known or potentially significant drug interactions,some of which may lead to

1. Loss of therapeutic effect of Daclavir and possible 2. development of resistance Dosage adjustments of concomitant medications or Daclavir 3. Possible clinically significant adverse reactions from greater exposures of concomitant drugs or Daclavir
The following serious adverse reactions are described below Serious Symptomatic Bradycardia When Co-administered with Sofosbuvir and Amiodarone.
In the ALLY-3 trial, 152 treatment-naive and treatment-experienced subjects with HCV genotype 3 infection were treated with Daclatasvir 60 mg once daily in combination with Sofosbuvir for 12 weeks. The most common adverse reactions (frequency of 10% or greater) were headache and fatigue.